Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III dose-response study of SMP-508 (repaglinide) monotherapy in type 2 diabetes mellitus
jRCT2080220511Phase 3
- Sponsor
- Sumitomo Pharma
- Start
- Jan 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of repaglinide in type 2 diabetes mellitus (T2DM), sponsored by Sumitomo Pharma.
02
Drugs
repaglinide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on jRCT2080220511.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080220511.